

*Optimal Cholesterol Management:
New Strategies*

Proceedings in this supplement are based on presentations and discussions that took place during an educational symposium titled, "Reinventing Treatment of Dyslipidemia: Novel Therapeutic Targets," held in Anaheim, California, on November 10, 2001, prior to the 74th Annual Scientific Sessions of the American Heart Association.

The contents of this supplement have been developed under the direction of and peer reviewed by Gary Gerstenblith, MD, Professor of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, for CME accreditation.

SYMPOSIUM PANEL AND FACULTY

Chair

Daniel J. Rader, MD

Director, Preventive Cardiovascular Medicine
and Lipid Research
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Faculty

H. Bryan Brewer, Jr, MD

Chief, Molecular Disease Branch
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

Lawrence L. Rudel, PhD

Professor of Pathology and Biochemistry
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Evan A. Stein, MD, PhD

Director of Research
Cholesterol Treatment Center
Metabolic and Atherosclerosis Research Center
Cincinnati, Ohio

Stephen D. Turley, PhD

Research Professor, Department of
Internal Medicine
University of Texas Southwestern
Medical Center at Dallas
Dallas, Texas

DISCLOSURE STATEMENT

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation.

It is also the policy of the publisher to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants have declared the following affiliations with corporate organizations.

■ **H. Bryan Brewer, Jr, MD**

Consultant To:

Merck and Co, Inc.
Pfizer
Merck/Schering-Plough
Kos Pharmaceuticals

■ **Daniel J. Rader, MD**

Research Grant Support From:

Bristol-Myers Squibb
AstraZeneca
Pfizer
Merck and Co, Inc.

Consultant To:

AstraZeneca
Pfizer
Merck/Schering-Plough

Honoraria From:

AstraZeneca
Bristol-Myers Squibb
Merck and Co, Inc.
Pfizer
Kos Pharmaceuticals

■ **Evan A. Stein, MD, PhD**

Research Grant Support From/Consultant To/

Honoraria From:

Merck and Co, Inc.
Schering-Plough
Novartis
AstraZeneca
Pfizer
Merck/Schering-Plough

■ **Stephen D. Turley, PhD**

Consultant To/Honoraria From:

Merck and Co, Inc.

The participant listed below declares no financial arrangement or affiliation with any corporate organizations.

■ **Lawrence L. Rudel, PhD**

NOTICE: In accordance with the ACCME Standards for Commercial Support, the audience is advised that one or more presentations in this continuing medical education activity contain reference(s) to unlabeled or unapproved uses of drugs or devices.

All faculty members have disclosed that their presentations will reference unlabeled/unapproved use of drugs or products (ezetimibe).